1332074

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL						
OMB Number:	3235-0076					
Expires:						
Estimated average burden						

16

hours per response

SEC U	ISE ONLY
Prefix.	Serial
DATE I	RECEIVED

Name of Offering / [] check if this is an amendment and name has changed, and indicate ch	ange.)
Primera Bibsystems, Inc Issuance and Sale of Series A-2 Convertible Preferred Stock	•
Filing Under (Check box(es) that apply): [] Rule 504 [] Rule 505 [X] Rul	e 506 [] Section 4(6) [] ULOE
Type of Filing: [X] New Filing [] Amendment	
A. BASIC IDENTIFICATION DATA	
Enter the information requested about the issuer	
Name of Issuer ([]] check if this is an amendment and name has changed, and indicate change.)
Primera Biosystems, Inc.	
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
171 Forbes Blvd., Suite 2000, Mansfield, MA 02048	(508) 618-2300
Address of Principal Business Operations (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
(if different from Executive Offices)	DDOo-
Dian in an in	LUCESCE!
Brief Description of Business	00_0
Pharmaceutical development company	SED 2
Type of Business Organization	OLI 2 4 2007 /
[X] corporation [] limited partnership, already formed [other (please specify):
[] business trust [] limited partnership, to be formed	other (please specify): THOMSON
Month Year	FINANCIAI
Actual or Estimated Date of Incorporation or Organization: [1][2] [0][4]	[X] Actual [] Estimated
Jurisdiction of Incorporation or Organization: Enter two-letter U.S. Postal Service Abbreviation	for State: [D][E]
(CN for Canada; FN for other foreign juris	diction)

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or U.S.C. 77d(6)

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date is was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.



		A. BASIC IDENTI	FICATION DATA		
 Each beneficial owner lof the issuer; 	suer, if the issue naving the powe and director of c	or has been organized with the to vote or dispose, or de- corporate issuers and of co			e of a class of equity securit artnership issuers; and
		[] Beneficial Owner	[X] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if indiverse, Martin	vidual)				Wallaging Faculo
Business or Residence Address (N c/o Primera Biosystems, Inc., 17					
Check Box(es) that Apply:	Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind Shiosaki, Ph.D., Kazumi	vidual)				
Business or Residence Address (N c/o Primera Biosystems, Inc., 17					
Check Box(es) that Apply: [Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind Cardosa, Ph.D., Mary Jane	vidual)			·	
Business or Residence Address (N c/o Primera Biosystems, Inc., 17					
Check Box(es) that Apply: [Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if indi Conway, Kenneth	vidual)		-, , , , , , , , 		
Business or Residence Address (N c/o Primera Biosystems, Inc., 17					
Check Box(es) that Apply:	Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind Foley, Todd	vidual)				•
Business or Residence Address (N c/o Primera Biosystems, Inc., 17					
Check Box(es) that Apply: [] Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind Hanham, Ph.D., Ann	vidual)				
Business or Residence Address (N c/o Primera Biosystems, Inc., 17					
Check Box(es) that Apply: [Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind McCarthy, Lawrence	vidual)				
Business or Residence Address (N c/o Primera Biosystems, Inc., 17					
Check Box(es) that Apply: [Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind Lila, Ph.D., Azmi Mohd	,				
Ducinace of Dacidanoa Addrace (N	1 10.				

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

c/o Primera Biosystems, Inc., 171 Forbes Blvd., Suite 2000, Mansfield, MA 02048

A. BASIC IDENTIFICATION DATA

2. Enter the information requested for the following:

- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and

Each general and	managing partner o	f partnership issuers.			
Check Box(es) that Apply:	[] Promoter	[X] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, Sention, Inc.	if individual)				
Business or Residence Addre One Richmond Sq., Provid		reet, City, State, Zip Code	•		
Check Box(es) that Apply:	[] Promoter	[X] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, Cooper, Leon N.	if individual)				
Business or Residence Addre c/o Primera Biosystems, In	•				
Check Box(es) that Apply:	[] Promoter	[X] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, Epstein, Mel H.	if individual)				
Business or Residence Addre c/o Primera Biosystems, In					
Check Box(es) that Apply:	[] Promoter	[X] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, i MPM Bioventures II-QP, I	•				
Business or Residence Addre c/o MPM Capital, L.P., 111					
Check Box(es) that Apply:	[] Promoter	[X] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, i The Burrill Biotechnology	· ·	•			
Business or Residence Addre c/o Primera Biosystems, In					
Check Box(es) that Apply:	[] Promoter	[X] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, i Malaysian Technology De	•	ation SDN BHD			
Business or Residence Addre Levels 3-4, MIDF Building	`				
Check Box(es) that Apply:	[] Promoter	[] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, i	f individual)				
Business or Residence Addre	ess (Number and St	reet, City, State, Zip Code)			
Check Box(es) that Apply:	[] Promoter	[] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first,	f individual)				
Business or Residence Addre	ess (Number and St	reet, City, State, Zip Code)			
			······································	* 14.	

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

B. INFORMATION ABOUT OFFERING

1.	Has the issuer sold, or does the issuer intend to sell, to non-ecredited investors in this offering?					Yes	No [X]							
2.	What is the minimum investment that will be accepted from any individual?													
4.	 Does the offering permit joint ownership of a single unit? Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only. 							No [X]						
Ful	l Name	(Last nam	e first, if in	dividual)										
N/A														
Bus	iness o	r Residend	æ Address	(Number an	d Street, Cr	ty, State, Zi	p Code)							
Nar	ne of A	ssociated	Broker or I	Dealer										
						to Solicit Pr	ırchasers							States
	AL]	[AK]	(AZ)	individual ([AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]		
(II)	L j	[N]	[IA]	[KS]	[KY]	[LA]	(ME)	[MD]	[MA]	[MI]	[MN]	[MS]	[M	oj
-	/IT] :J]	[NE] [SC]	[NV] [SD]	[NH] [TN]	[NJ] [TX]	[NM] [UT]	[NY] [VT]	[NC] [VA]	[ND] [WA]	[OH] [WV]	[OK] [WI]	[OR] [WY]	[P [P	
Ful	l Name	(Last nam	e first, if in	dividual)										
Bus	siness o	Residenc	æ Address	(Number an	d Street, Ci	ty, State, Zi	Code)							
Nar	ne of A	ssociated	Broker or D	Dealer										
			-			to Solicit Pr	ırchasers							
	(Check ' AL]	"All State [AK]	s" or check [AZ]	individual (States) [CA]	[CO]	[CT]	[DE]	[DC]	{ FL]	[GA]	[HI]		
-	L]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[M	
-	(T) .I]	[NE] [SC]	[NV] [SD]	[NH] [TN]	[NJ] [TX]	[NM] [TU]	[NY] [VT]	[NC] [VA]	[ND] [WA]	(OH) (WV)	[OK] [WI]	[OR] [WY]	[P.	
_			e first, if in			[OI]	[41]	[VA]	[WA]	(***)	[" 1]	[** 1]		<u> </u>
Bus	iness o	Residenc	æ Address ((Number and	d Street, Ci	ty, State, Zij	Code)					<u>.</u>		
Nar	ne of A	ssociated	Broker or I	Dealer										
											<u></u>			
				as Solicited individual :		to Solicit Pu	ırchasers							States
	AL]	[AK]	S OF CHECK	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]		
	Lj	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[M	0]
	IT] RL)	[NE] [SC]	[NV] [SD]	[NH] [TN]	[NJ] [TX]	[NM] [UT]	[NY] [VT]	[NC] [VA]	[ND] [WA]	[OH] [WV]	[OK] [WI]	[OR] [WY]	[P.	
	~ 1	11	[~~]	1 1	[]	[]		[]		··· ··· ·· · · · · · · · · · · · · · ·				

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1. Enter the aggregate offering price of securities included in this offering and the total amount already

	Type of Security Debt	Aggregate Offering Price \$ 0	Amount Already Sold \$ 0
	Equity - Series A-2 Convertible Preferred Stock	\$ 2,500,000	\$ 2,398,245
	[] Common [X] Preferred	• •	• 0
	Convertible Securities (including warrants)	\$ <u>0</u>	\$0 \$
	Other—	<u> </u>	<u> </u>
	***************************************	S <u> </u>	\$ <u>0</u>
	Total	\$ <u>2,500,000</u>	\$ <u>2,398,245</u>
2.	Answer also in Appendix, Column 3, if filing under ULOE. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
		Number Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	17	\$ 2,398,245
	Non-accredited Investors	0	\$ <u>0</u>
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C—Question 1.		
	m	Type of	Dollar Amount
	Type of Offering Rule 505	Security 0	Sold \$ 0
	Regulation A	0	\$0 \$0
	Rule 504.	0	\$ 0
	Total	0	\$ 0
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		
	Printing and Engraving Costs		
	Legal Fees		
	ACCOUNTING FEES	[] \$	0
		r i c	Λ.
	Engineering Fees		
		[js	0

•	C. OFFERING PRICE, NUMBER OF IN	NVESTORS, EXPENSES AND USE OF	F PROCEEDS (con	tinued)	
5.	b. Enter the difference between the aggregate offering price and total expenses furnished in response to Part C—Quergross proceeds to the issuer."	stion 4.a. This difference is the "adjuste	ed ed	\$	2,485,000
	for each of the purposes shown. If the amount for any pur check the box to the left of the estimate. The total of th				
	gross proceeds to the issuer set forth in response to Part C-				
			Payments to		
			Officers, Directors, &	2. 1	Doumanta to
			Affiliates		Payments to Others
	Salaries and fees		[] \$		
	Purchase of real estate		[] s	. [] <u>.</u>	<u>0</u>
	Purchase, rental or leasing and installation of machinery		[] \$	1 1 5	
	Construction or leasing of plant buildings and facilities.		[] S (פוו ו	0
	Acquisition of other businesses (including the value of s		.,		
	offering that may be used in exchange for the assets or s				
	issuer pursuant to a merger)		[] S	[]\$_	0
	Repayment of indebtedness		[]\$	[] \$_	0
	Working capital		[] \$0		
	Other (specify):		[]\$0	[] S_	0
	Column Totals		[]\$	[X] S	
	Total Payments Listed (column totals added)			[X] \$ _	2,485,000
	D.	FEDERAL SIGNATURE			
sig	e issuer has duly caused this notice to be signed by the unc nature constitutes an undertaking by the issuer to furnish to ormation furnished by the issuer or any non-accredited invest	o the U.S. Securities and Exchange Com	mission, upon writt		
Is	suer (Print or Type)	Signature		Date	<u> </u>
	rimera Biosystems, Inc.	Man ()		Septembe	r_12, 2007
N	ame of Signer (Print or Type)	Title (Print or Type)			
N	Iartin Verhoef	President & Chief Executive Officer			Į.

ATTENTION

Intentional misstatements or omission of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

